Pharma Strategy Blog

Commentary on Pharma & Biotech Oncology / Hematology New Product Development

Posts tagged ‘CRC’

Unravelling early colorectal cancer: the links between ROS, DNA methylation and inflammatory responses

During yesterday’s discussion with Dr Ray DuBois (MD Anderson Cancer Center) about inflammation and methylation, the topic of CpG island methylator phenotype (CIMP) in colorectal cancer (CRC) came up as you can see from the brief audio clip below:

Steve Baylin’s paper sounded most interesting, so I tracked it down – see O’Hagan et al., (2011) in the References below for the direct link.

CIMP is interesting to look at because it can occur in some 30% of colorectal cancer cases and has been previously shown to be an independent predictor of survival with 5FU in early or adjuvant CRC (van Rijnsoever, 2003). It is, therefore, a potentially useful molecular marker in this disease.

3 Comments

AACR Colorectal Cancer Meeting: Biology to Therapy

Later today I’m heading off to Philadelphia to attend a special conference at the American Society of Cancer Research (AACR) meeting on colorectal cancer entitled Biology to Therapy.  There’s still time to pack a back and head on down as the main meeting doesn’t start until tomorrow.

Tonight, I’m very much looking forward to the Keynote from Prof Bert Vogelstein (Johns Hopkins) who is doing a talk entitled:

“Colorectal cancer genomes and their implications for basic and applied research.”

You can check out the full program here.

1 Comment